CPR Pharma Services Pty Ltd, Australia
9
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
11.1%
1 terminated/withdrawn out of 9 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.
Role: collaborator
Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994
Role: collaborator
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
Role: collaborator
Drug Drug Interaction Study for EYP001 With Entecavir
Role: collaborator
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers
Role: collaborator
Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects
Role: collaborator
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430
Role: collaborator
A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™
Role: collaborator
Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers
Role: collaborator
All 9 trials loaded